User:Mr. Ibrahem/Umbralisib

Umbralisib, sold under the brand name Ukoniq, is a medication which was previously used to treat marginal zone lymphoma (MZL) and follicular lymphoma (FL). It was taken by mouth.

Common side effects include kidney problems, diarrhea, tiredness, nausea, low neutrophils, muscle pain, low platelets, low red blood cells, upper respiratory tract infection, and rash. Other side effects may include infections, liver problems, and allergic reactions. Use in pregnancy may harm the baby. It is a kinase inhibitor that blocks PI3K-delta and casein kinase CK1-epsilon.

Umbralisib was approved for medical use in the United States in 2021. However, due to concerns of worsened outcomes it was removed from the market in 2022. Efforts to license in Europe and the United Kingdom have been discontinued.